Xenon Pharmaceuticals Inc.

196 articles about Xenon Pharmaceuticals Inc.

• Xenon Pharmaceuticals Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA

  6/21/2022

  XEN1101 Phase 3 program for the treatment of focal onset seizures to be initiated in the second half of 2022 and New Drug Application expected to be submitted after completion of first Phase 3 clinical trial (X-TOLE2) along with the completed Phase 2b (X-TOLE) clinical trial.

• Xenon Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference

  6/1/2022

  Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and present at the 2022 Jefferies Healthcare Conference to be held June 8-10, 2022 in New York, NY.

• Xenon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

  5/10/2022

  Xenon Pharmaceuticals Inc., a neurology-focused biopharmaceutical company, reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.

• Xenon Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial to Evaluate XEN1101 as a Treatment for Major Depressive Disorder (MDD)

  5/3/2022

  Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the initiation of a Phase 2 randomized, double-blind, placebo-controlled, multicenter clinical study – called the “X-NOVA” clinical trial – to evaluate the safety, tolerability, and efficacy of XEN1101 in Major Depressive Disorder (MDD).

• Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Corporate Update

  5/3/2022

  Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its first quarter 2022 financial and operating results after the close of U.S. financial markets on Tuesday, May 10, 2022.

• Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences - Apr 25, 2022

  4/25/2022

  Xenon Pharmaceuticals Inc., a neurology-focused biopharmaceutical company announced that Xenon’s management team will participate in the following investor conferences.

• Xenon Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference

  4/4/2022

  Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and a fireside chat at the 21st Annual Needham (Virtual) Healthcare Conference.

• Xenon Pharmaceuticals to Present at Stifel 2022 CNS Days

  3/22/2022

  Xenon Pharmaceuticals Inc., a neurology-focused biopharmaceutical company, announced that management will participate in one-on-one investor meetings and a fireside chat at the Stifel 2022 CNS Days conference.

• Xenon Pharmaceuticals Reports 2021 Financial Results and Provides Corporate UpdateConference Call at 4:30 pm ET Today

  3/1/2022

  Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the year ended December 31, 2021 and provided a corporate update.

• Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Year-End 2021 Financial Results and Provide Corporate Update

  2/22/2022

  Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its financial results for the year ended December 31, 2021 and provide a corporate update after the close of U.S. financial markets on Tuesday, March 1, 2022.

• Xenon Pharmaceuticals to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

  2/14/2022

  Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced its participation in one-on-one investor meetings and a virtual fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference.

• Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $15.0 Million Regulatory Milestone

  1/12/2022

  Xenon Pharmaceuticals Inc. today announced that its collaboration to develop treatments for epilepsy with Neurocrine Biosciences, Inc. (Nasdaq: NBIX) achieved a regulatory milestone, which has triggered an aggregate payment of $15.0 million to Xenon.

• Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2022

  1/10/2022

  Xenon Pharmaceuticals Inc. today outlined its key milestones for 2022.

• Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2021)

  12/3/2021

  Xenon Pharmaceuticals Inc. today announced that it will provide updates on its proprietary, neurology programs at the Annual Meeting of the American Epilepsy Society (AES 2021).

• Xenon Pharmaceuticals Presents Additional Positive Data from Phase 2b ‘X-TOLE’ Clinical Trial at the Annual Meeting of the American Epilepsy Society (AES 2021)

  12/3/2021

  Xenon Pharmaceuticals Inc. today announced that additional positive data from new sub-analyses of the Phase 2b X-TOLE clinical trial will be presented in a scientific poster entitled “Phase 2b Efficacy and Safety of XEN1101.

• Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences - Nov 12, 2021

  11/12/2021

  Xenon Pharmaceuticals Inc., a neurology-focused biopharmaceutical company, announced that Ian Mortimer, Xenon’s President and Chief Executive Officer, along with Sherry Aulin, Xenon’s Chief Financial Officer, will participate virtually in the following investor conferences.

• Xenon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

  11/10/2021

  Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.

• Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide Corporate Update

  11/3/2021

  Xenon Pharmaceuticals Inc. today announced it will report its third quarter 2021 financial and operating results after the close of U.S. financial markets on Wednesday, November 10, 2021.

• Xenon Pharmaceuticals Announces Closing of $345 Million Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

  10/8/2021

  Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 10,000,000 common shares, which includes 1,525,423 shares sold upon the full exercise of the underwriters’ option to purchase additional shares, and pre-funded warrants to purchase 1,694,915 common shares.

• Xenon Pharmaceuticals Announces Pricing of $300.0 Million Public Offering

  10/6/2021

  Xenon Pharmaceuticals Inc., a clinical stage biopharmaceutical company, announced the pricing of its underwritten public offering of 8,474,577 common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 1,694,915 common shares pursuant to its existing shelf registration statement.